View printer-friendly version << Back

Novavax Executive Receives CDC Science Award

ROCKVILLE, Md., June 21 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that Rick A. Bright, Ph.D., vice president of global influenza programs, and co-authors received the Centers for Disease Control's Charles C. Shepard Science Award for the most outstanding peer- reviewed publication by CDC scientists during the preceding year. The Shepard awards honor outstanding publications and lifetime achievements of CDC scientists in memory of Dr. Charles C. Shepard, an internationally recognized microbiologist whose career was marked by the pursuit of scientific excellence.

Dr. Bright and former colleagues were honored for publication of "Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice," published in the February 11, 2006 issue of The Lancet, which described methods for developing a vaccine to prevent avian influenza.

Dr. Bright currently heads up Novavax's influenza vaccine development programs utilizing the Company's proprietary VLP technology in their development for human use. Before he joined Novavax in 2006, Dr. Bright was a research scientist and team leader of the CDC's influenza antiviral drug program where he published several landmark papers on global antiviral drug resistance among circulating influenza viruses. From 1997 to 2006, Dr. Bright held various immunology and research positions at the CDC and other research institutions where his research focused on human and avian influenza viruses and vaccine development for influenza. He received a Ph.D. in immunology and molecular and viral pathogenesis from Emory University.

About Novavax

Novavax Inc. is committed to leading the global fight against infectious disease by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. Novavax's particulate vaccines closely match disease-causing viruses while lacking the genetic material to cause disease, which provides potential for greater immune protection at lower doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.

SOURCE Novavax, Inc.

CONTACT: Tricia Richardson of Novavax, Inc.,

This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. By clicking ‘Accept’ you are indicating your consent for us to place these cookies. For more information, please read our Privacy Policy or manage your cookie settings.